Welcome | Sign In
ECommerceTimes.com
Science

Senate Votes to Loosen Stem Cell Restrictions, Veto Likely

Print Version
E-Mail Article
Reprints
Senate Votes to Loosen Stem Cell Restrictions, Veto Likely

The Senate has voted to ease limits on embryonic stem cell research, but President Bush has vowed to veto any such measure that reaches his desk. Stem cells are created in the first days after conception and are collected from leftover frozen embryos that result from in vitro fertilization at fertility clinics; the embryos are destroyed in the process.


Tips to Integrate Social Media into Your Day-to-Day Media Monitoring
Is social media part of your PR and marketing strategy? This white paper is filled with tips on how to listen to conversations about your brand in the media (social media, print, TV and internet) using the latest tools and techniques. Download Now.

The U.S. Senate passed legislation on Wednesday to ease restrictions on embryonic stem cell research, but the 63-34 vote in favor of the bill fell short of the two-thirds majority necessary to override an expected presidential veto.

The House passed similar legislation earlier this year and is expected to adopt the Senate's version.

S.5, or the Stem Cell Research Enhancement Act, would amend the Public Health Service Act to require the Secretary of Health and Human Services to conduct and support research that uses human embryonic stem cells, regardless of the date on which the stem cells were derived from a human embryo. Currently, federally funded scientists can conduct research on embryonic stem cells only if the cells were derived before Aug. 9, 2001, at 9 p.m.

'Exciting' Potential

Stem cells are created in the first days after conception and are collected from leftover frozen embryos that result from in vitro fertilization at fertility clinics; the embryos are destroyed in the process.

Stem cells are thought to hold great promise for medical research into many diseases.

"This is the one bill that, at long last, will unleash some of the most exciting and promising research of modern times," said Sen. Tom Harkin (D-Iowa), who is the lead sponsor of the legislation. "S.5 will lift the president's arbitrary restrictions on stem cell research and bring hope to millions of Americans who suffer from juvenile diabetes, Parkinson's, cancer, spinal cord injuries and many other diseases and conditions."

Ethical Questions

Using human embryo stem cells has been highly controversial, raising ethical questions.

"This bill crosses a moral line that I and many others find troubling," Bush said in a statement after the Senate vote. "If it advances all the way through Congress to my desk, I will veto it."

"We agree with the president on this issue," Douglas Johnson, legislative director for the National Right To Life Committee, told TechNewsWorld. "We have an ethical objection to using human embryos, and we are opposed to this legislation. We fully expect that the president's veto will be sustained."

Regarding the potential of stem cell research, "not a single human patient has yet been helped by stem cells obtained by killing human embryos," Johnson asserted. "Meanwhile, many thousands of human patients have been helped with other types of stem cells, obtained in noncontroversial ways that do not require harming human embryos."

Unique Benefits

Yet those in the industry emphasize that embryonic stem cells offer unique benefits for research into diseases and their treatment.

"We now have stem cell lines that include genetic markers for specific diseases," Andrew Cohn, a spokesperson for WiCell Research Institute, told TechNewsWorld. "It would be tremendous for researchers to have lines that were predetermined for ALS (Amyotrophic Lateral Sclerosis), for example, and to compare them with those of people who don't. There are countless scientific reasons why additional lines would be helpful."

With an upcoming presidential veto more or less certain, of course, that potential doesn't seem likely to be realized anytime soon. However, a trial currently underway by Geron, in which embryonic cells are being used to treat spinal injuries, may go a long way toward convincing opponents in the future, Cohn added.

For now, "I think scientists will continue to move forward, but more slowly than they would," Cohn said. "And I assume that whoever the next the president is, this policy will be gone in a few years."


Print Version E-Mail Article Reprints More by Katherine Noyes


More by Katherine Noyes

Does Wine Make Linux Too Loose?
November 05, 2009
For those Wine aficionados out there, beware of the remote possibility that your Linux system could be infected by Windows-seeking malware. "WINE running a Windows virus is nothing more than a 'stupid Linux trick' ... for now," said Slashdot blogger hairyfeet. But if the year of the Linux desktop ever arrives, he wonders, can Linux hold up to a "tidal wave of stupidity"?
PayPal Gets Friendly With Developers
November 04, 2009
PayPal is aiming to remove some of the obstacles to wider use of its service by giving developers the tools they need to embed its functionality directly in applications. That means a user could make a purchase without leaving a mobile game, for example. "The network is the platform on which the potential of digital money will be fully realized," said PayPal President Scott Thompson.
Firefox 3.6 Tweaks Are Mostly Under the Hood
November 03, 2009
For users, Mozilla's new Firefox 3.6 beta includes personas -- a new feature for changing Firefox skins -- and it sends alerts when it encounters out-of-date plug-ins. Developers may be more interested in some of the more subtle changes, however -- e.g., support for new CSS, DOM and HTML5 Web technologies, as well as support for image rendering and multiple background images.
Don't miss a story -- sign up for our FREE e-mail newsletters and view the latest headlines at a glance.
Tech News Flash [ View Sample ]
E-Commerce Minute [ View Sample ]
ECT News Network Weekly Newsletter [ View Sample ]
Shortcuts
ECT News Network Information
Reader Services
Corporate
ECT News Network